ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 411

Frequency and Staining Patterns of Antinuclear Antibodies in Myositis Patients Without Known Myositis-specific Autoantibodies

Maria casal-Dominguez1, Iago Pinal-Fernandez 1, Ana Marin 2, Maria Teresa Sanz-Martinez 2, Andres Baucells-de la Pena 3, Katherine Pak 4, Yuji Hosono 1, Lisa Christopher-Stine 5 and Andrew L Mammen 4, 1NIH, Bethesda, 2Vall d'Hebron Hospital, Barcelona, Spain, 3Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4National Institutes of Health, Bethesda, 5Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Antinuclear antibodies (ANA), myositis and immunology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Muscle Biology, Myositis & Myopathies Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Objective:To determine the frequency and staining patterns of antinuclear antibodies (ANA) in myositis patients who do not have known myositis-specific autoantibodies.

Methods: Material and methods:Sera from dermatomyositis (DM), inclusion body myositis (IBM), and polymyositis (PM)patients without known myositis-specific autoantibodies, as well as serum from healthy control patients, were tested for ANA by indirect immunofluorescence (IIF) assay on HEp-2 cells. In sera from ANA-positive patients and controls, the pattern of positivity was classified according to the International Consensus on ANA Patterns (ICAP).  The prevalence and pattern of ANA in different myositis subgroups was compared to those of healthy sera.

Results: Results:Sera from189 myositis-specific autoantibody-negative myositis patients (76 DM, 50 IBM and 63 PM) and 91 healthy comparators were included in the study. Most DM sera were moderately or strongly ANA positive (53%, p< 0.001).  Only 33%, 22%, and 15% were moderately or strongly ANA positive in the PM, IBM, and healthy control groups, respectively (all p >0.05). ANA positivity was mostly nuclear (as opposed to cytoplasmic or mitotic) and the most common pattern was fine speckled. The only difference in ANA pattern among myositis subgroups was a higher prevalence of a nuclear fine speckled pattern in DM patients (61%, p=0.02).

Conclusion: Conclusions:Most myositis-specific autoantibody-negative DM patients have moderate/strong ANA positivity, predominantly in a fine speckled pattern. In contrast, myositis-specific autoantibody-negative PM and IBM patients show similar rates of ANA positivity as healthy controls. These findings suggest that currently ANA-positive unidentified autoantibodies are more likely to exist in DM patients than in IBM or PM.


Disclosure: M. casal-Dominguez, None; I. Pinal-Fernandez, None; A. Marin, None; M. Sanz-Martinez, None; A. Baucells-de la Pena, None; K. Pak, None; Y. Hosono, None; L. Christopher-Stine, AstraZeneca (Medimmune) Kezar, 5, Corbus Pharmaceuticals, 2, CSL Behring, 2, Inova Diagnostics, 7, Kezar, 2, Mallinckrodt Pharmaceuticals, 5, Novartis, 2, OptionCare, 5, Pfizer, 2; A. Mammen, None.

To cite this abstract in AMA style:

casal-Dominguez M, Pinal-Fernandez I, Marin A, Sanz-Martinez M, Baucells-de la Pena A, Pak K, Hosono Y, Christopher-Stine L, Mammen A. Frequency and Staining Patterns of Antinuclear Antibodies in Myositis Patients Without Known Myositis-specific Autoantibodies [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/frequency-and-staining-patterns-of-antinuclear-antibodies-in-myositis-patients-without-known-myositis-specific-autoantibodies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequency-and-staining-patterns-of-antinuclear-antibodies-in-myositis-patients-without-known-myositis-specific-autoantibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology